A complete and durable response to denileukin diftitox in a patient with mycosis fungoides - 29/08/11
Doi : 10.1067/mjd.2002.227
Abstract |
We describe a patient with stage IA mycosis fungoides treated with denileukin diftitox as part of a randomized phase III trial. The patient had a rapid and complete response and has remained in remission for more than 5 years without maintenance therapy. Although denileukin diftitox is not usually considered for patients with early-stage mycosis fungoides, our experience provides anecdotal evidence that fusion toxin therapy may be worth considering as a treatment for patients with stage I disease. (J Am Acad Dermatol 2003;48:275-6.)
Le texte complet de cet article est disponible en PDF.Plan
 | Funding sources: There was no funding received for this work. Seragen, Inc (now part of Ligand Pharmaceuticals, Inc) funded the clinical trial referred to in this report. |
| Conflict of interest: None. |
 | Reprints not available from authors. |
| Correspondence: David P. Fivenson, MD, Department of Dermatology, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202-2689. E-mail: dfivens1@hfhs.org. |
| ♢ | Published online December 20, 2002. |
| ♢♢ | 0190-9622/2002/$30.00 + 0 |
© 2002
American Academy of Dermatology, Inc. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 48 - N° 2
P. 275-276 - février 2003 Retour au numéro
Article précédent
- Iotaderma 109
- Basal cell carcinoma of the toenail unit
- Thomas Herzinger, Michael Flaig, Roman Diederich, Martin Röcken
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?